Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3683MR)

This product GTTS-WQ3683MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3683MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11996MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ6929MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ12668MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ987MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ3817MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ10874MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ9973MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW